Jelmer Willems

Jelmer Willems

Auto-generated profile, based on publicly available information

Jelmer Willems

VectorY Therapeutics B.V., Science Park 408, Amsterdam 1098 XH, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
JWJelmer Willems
Jelmer Willems
AJArthur P H De Jong
Arthur P H De Jong
NSNicky Scheefhals
Nicky Scheefhals
EMEline Mertens
Eline Mertens
LCLisa A E Catsburg
Lisa A E Catsburg
HMHarold D MacGillavry
Harold D MacGillavry
The correct subcellular distribution of proteins establishes the complex morphology and function of neurons. Fluorescence microscopy techniques are invaluable to investigate subcellular protein distribution, but they suffer from the limited ability to efficiently and reliably label endogenous proteins with fluorescent probes. We developed ORANGE: Open Resource for the Application of Neuronal Genome Editing, which mediates targeted genomic integration of epitope tags in rodent dissociated neuronal culture, in organotypic slices, and in vivo. ORANGE includes a knock-in library for in-depth investigation of endogenous protein distribution, viral vectors, and a detailed two-step cloning protocol to develop knock-ins for novel targets. Using ORANGE with (live-cell) superresolution microscopy, we revealed the dynamic nanoscale organization of endogenous neurotransmitter receptors and synaptic scaffolding proteins, as well as previously uncharacterized proteins. Finally, we developed a mechanism to create multiple knock-ins in neurons, mediating multiplex imaging of endogenous proteins. Thus, ORANGE enables quantification of expression, distribution, and dynamics for virtually any protein in neurons at nanoscale resolution.

15 October 2022
Verified
Thesis
Open access
JWJelmer Willems
Jelmer Willems

2 June 2026 in Trends in Biotechnology
Verified
Journal Article
Open access
LJLinda A. de Jong
Linda A. de Jong
JWJelmer Willems
Jelmer Willems
AWAdriaan H. de Wilde
Adriaan H. de Wilde
MSMels Schrama
Mels Schrama
BSBarbara P. Sanders
Barbara P. Sanders
Gorben PijlmanGorben Pijlman
Gorben Pijlman
In vivo gene therapy is rapidly advancing to treat patients with a wide range of genetic disorders. Recombinant adeno-associated virus (rAAV) vectors provide long-term gene expression, low immunogenicity, and adaptable tissue tropism. Production of rAAV in insect cells with the Baculovirus Expression Vector System currently depends on infection with multiple baculoviruses encoding AAV genes Rep, Cap, and the therapeutic gene. In this research article, we present simplified rAAV production using a single baculovirus vector with improved genetic stability, called BAC6Rep, with AAV Rep locked into the baculovirus genome. Robust AAV Rep and Cap expression was maintained upon serial passaging, and high rAAV yields (up to 3.5e11 genome copies/ml) were obtained at high and low multiplicities of infection. Next-generation sequencing revealed a significantly improved genetic stability of BAC6Rep, which can now be used as a plug-in hybrid vector for flexible insertion of different AAV Cap and gene of interest tailored to the therapeutic target.